DE102005051789B4 - Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen - Google Patents

Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen Download PDF

Info

Publication number
DE102005051789B4
DE102005051789B4 DE102005051789.7A DE102005051789A DE102005051789B4 DE 102005051789 B4 DE102005051789 B4 DE 102005051789B4 DE 102005051789 A DE102005051789 A DE 102005051789A DE 102005051789 B4 DE102005051789 B4 DE 102005051789B4
Authority
DE
Germany
Prior art keywords
polypeptide
amino acid
acid sequence
bont
homo sapiens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102005051789.7A
Other languages
German (de)
English (en)
Other versions
DE102005051789A1 (de
Inventor
Andreas Rummel
Stefan Mahrhold
Thomas Binz
Johannes Wilhelm Bigalke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toxogen GmbH
Original Assignee
Toxogen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102005051789.7A priority Critical patent/DE102005051789B4/de
Application filed by Toxogen GmbH filed Critical Toxogen GmbH
Priority to NZ567312A priority patent/NZ567312A/en
Priority to PCT/EP2006/010420 priority patent/WO2007048638A2/de
Priority to AU2006308122A priority patent/AU2006308122B2/en
Priority to JP2008537015A priority patent/JP2009513118A/ja
Priority to EP06806613A priority patent/EP1940874B1/de
Priority to US12/084,074 priority patent/US8476024B2/en
Priority to ES06806613T priority patent/ES2379513T3/es
Priority to CA2627457A priority patent/CA2627457C/en
Priority to AT06806613T priority patent/ATE539088T1/de
Priority to KR1020087011531A priority patent/KR20080068069A/ko
Publication of DE102005051789A1 publication Critical patent/DE102005051789A1/de
Priority to ZA200803403A priority patent/ZA200803403B/xx
Application granted granted Critical
Publication of DE102005051789B4 publication Critical patent/DE102005051789B4/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE102005051789.7A 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen Expired - Fee Related DE102005051789B4 (de)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE102005051789.7A DE102005051789B4 (de) 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
CA2627457A CA2627457C (en) 2005-10-28 2006-10-30 Botulinum neurotoxin a protein receptor and uses thereof
AU2006308122A AU2006308122B2 (en) 2005-10-28 2006-10-30 Botulinum neurotoxin A protein receptor and uses thereof
JP2008537015A JP2009513118A (ja) 2005-10-28 2006-10-30 ボツリヌス神経毒ａタンパク質受容体およびその使用
EP06806613A EP1940874B1 (de) 2005-10-28 2006-10-30 Der botulinus neurotoxin a proteinrezeptor und seine anwendungen
US12/084,074 US8476024B2 (en) 2005-10-28 2006-10-30 Botulinum neurotoxin a protein receptor and uses thereof
NZ567312A NZ567312A (en) 2005-10-28 2006-10-30 Botulinum neurotoxin a protein receptor and uses thereof
PCT/EP2006/010420 WO2007048638A2 (de) 2005-10-28 2006-10-30 Der botulinus neurotoxin a proteinrezeptor und seine anwendungen
AT06806613T ATE539088T1 (de) 2005-10-28 2006-10-30 Der botulinus neurotoxin a proteinrezeptor und seine anwendungen
KR1020087011531A KR20080068069A (ko) 2005-10-28 2006-10-30 보툴리눔 신경독소 ａ형 단백질 수용체 및 그의 이용
ES06806613T ES2379513T3 (es) 2005-10-28 2006-10-30 Receptor de proteína de la neurotoxina botulínica A y sus utilizaciones
ZA200803403A ZA200803403B (en) 2005-10-28 2008-04-17 Botulinum neurotoxin a protein receptor and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005051789.7A DE102005051789B4 (de) 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen

Publications (2)

Publication Number Publication Date
DE102005051789A1 DE102005051789A1 (de) 2007-05-10
DE102005051789B4 true DE102005051789B4 (de) 2014-08-07

Family

ID=37770829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005051789.7A Expired - Fee Related DE102005051789B4 (de) 2005-10-28 2005-10-28 Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen

Country Status (12)

Country Link
US (1) US8476024B2 (https=)
EP (1) EP1940874B1 (https=)
JP (1) JP2009513118A (https=)
KR (1) KR20080068069A (https=)
AT (1) ATE539088T1 (https=)
AU (1) AU2006308122B2 (https=)
CA (1) CA2627457C (https=)
DE (1) DE102005051789B4 (https=)
ES (1) ES2379513T3 (https=)
NZ (1) NZ567312A (https=)
WO (1) WO2007048638A2 (https=)
ZA (1) ZA200803403B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US8771707B2 (en) * 2008-09-30 2014-07-08 Wisconsin Alumni Research Foundation Botulinum neurotoxin E receptors and uses thereof
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
UA116985C2 (uk) 2012-05-30 2018-06-11 Президент Енд Феллоуз Оф Гарвард Колледж Рекомбінантний ботулінічний нейротоксин
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
KR101670188B1 (ko) 2015-11-09 2016-10-27 충북대학교 산학협력단 보툴리눔 신경독소 ｅ형에 특이적인 폴리펩타이드 및 이의 용도
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR101958312B1 (ko) * 2017-09-06 2019-07-02 국방과학연구소 보툴리눔 a형 독소에 대한 항체
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying anti clostridial neurotoxin compounds
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤
WO2025089343A1 (ja) * 2023-10-25 2025-05-01 株式会社Jiksak Bioengineering 抗シナプス小胞糖タンパク質２ｃ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016233A2 (en) 2002-10-31 2005-02-24 Wisconsin Alumni Research Foundation Botulinum neurotoxin b receptors and use thereof
CA2484115C (en) * 2002-12-03 2007-01-30 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Internet-Recherche am 15.05.2006: www.ncbi.nlm. nih.gov/entrez, Sequenzvergleich von NP_113781 mit NP_055794 *
Internet-Recherche am 15.05.2006: www.ncbi.nlm. nih.gov/entrez, synaptic vesicle glycoprotein 2c (Homo sapiens) Accession Number: NP_055794 *
Internet-Recherche am 15.05.2006: www.ncbi.nlm. nih.gov/entrez, synaptic vesicle glycoprotein 2c (Rattus norvegicus) Accession Number: NP_113781 *
JANZ, R. [u.a.]: SV2C is a synaptic vesicle protein with an usually restricted localization: anatomy of a synaptic protein family. Neuroscience (1999) 94 (4) 1279-1290 *

Also Published As

Publication number Publication date
US8476024B2 (en) 2013-07-02
AU2006308122B2 (en) 2011-06-30
NZ567312A (en) 2011-09-30
EP1940874A2 (de) 2008-07-09
EP1940874B1 (de) 2011-12-28
DE102005051789A1 (de) 2007-05-10
WO2007048638A2 (de) 2007-05-03
KR20080068069A (ko) 2008-07-22
US20090252722A1 (en) 2009-10-08
ZA200803403B (en) 2009-02-25
CA2627457C (en) 2014-05-13
JP2009513118A (ja) 2009-04-02
WO2007048638A3 (de) 2007-07-26
CA2627457A1 (en) 2007-05-03
ES2379513T3 (es) 2012-04-26
AU2006308122A1 (en) 2007-05-03
ATE539088T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
DE102005051789B4 (de) Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
EP3181578B1 (de) Carrier zum targeting von nervenzellen
DE60032367T3 (de) Aktivierbare rekombinante neurotoxine
Rummel et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation‐dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor
Hayashi et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.
EP1786832B1 (de) Transportprotein zum einbringen chemischer verbindungen in nervenzellen
DE69233157T2 (de) Rekombinanter thrombinrezeptor und verwandte arzneimittel
DE69434067T2 (de) Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes
Mahrhold et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves
Rummel Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity
DE60030429T2 (de) Neuronale, die exozytose hemmende peptide und diese enthaltende kosmetische und pharmazeutische zusammensetzungen
Weller et al. Chains and fragments of tetanus toxin: separation, reassociation and pharmacological properties
DE60123635T2 (de) Methode und zusammensetzung zur förderung von osteogenese
Wellhöner Tetanus and botulinum neurotoxins
Poulain et al. Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons
Khvotchev et al. α‐latrotoxin triggers transmitter release via direct insertion into the presynaptic plasma membrane
DE69631516T2 (de) Familie von Kaliumkanälen von Säugetieren, deren Klonierung und Anwendung für Drogenscreening
EP1319022B1 (de) Breit einsetzbares verfahren zur identifizierung von modulatoren von g-protein gekoppelten rezeptoren
Apland et al. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25
Agnew et al. Voltage-sensitive sodium channels: molecular structure and function
DE69932351T2 (de) DNS-kodierende Fusionsproteine, die durch Kupfer(II)-Ionen spezifisch spaltbar sind
AT412514B (de) Verfahren zum screenen von npt2b-modulierenden mitteln
DE19808258A1 (de) Kopfaktivator-bindendes Protein oder Polypeptid und Verfahren zur Suche nach funktionalen Agonisten oder Antagonisten unter Verwendung von kopfaktivatorbindendem Protein oder Polypeptid
GARCÍA-SÁINZ Multiple species and isoforms of Bordetella pertussis toxin substrates

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R082 Change of representative

Representative=s name: DR. VOLKER VOSSIUS PATENTANWAELTE RECHTSANWAELTE P

Representative=s name: DR. VOLKER VOSSIUS PATENTANWAELTE RECHTSANWAEL, DE

Representative=s name: DR. VOLKER VOSSIUS PATENTANWAELTE PARTNERSCHAF, DE

R018 Grant decision by examination section/examining division
R020 Patent grant now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee